Table 2.

Treatment response according to treatment arm for randomized patients and transplant recipients only

	Randomized patients				Transplant recipients
	Auto-SCT n = 54		Allo-SCT n = 49		Auto-SCT* n = 41		Allo-SCT n = 26
	n/group (%)	95% CI	n/group (%)	95% CI	n/group (%)	95% CI	n/group (%)	95% CI
Treatment response
CR/CRu	21/54 (39)	26-53	25/49 (51)	36-66	26/41 (63)	47-78	19/26 (73)	52-88
CR/CRu/untreated PR	30/54 (56)	41-69	28/49 (57)	42-71	36/41 (88)	74-96	21/26 (81)	61-93
Relapse after CR/CRu	7/21 (33)	15-57	3/25 (12)	3-31	10/26 (38)	20-59	0/19 (0)	0-18
Relapse after CR/CRu/untreated PR	9/30 (30)	15-49	4/28 (14)	4-33	13/36 (36)	21-54	0/21 (0)	0-16
EFS events
PD at the end of therapy	19/54 (35)		16/49 (33)		5/41 (12)		1/26 (4)
Relapse after CR, CRu	7/54 (13)		3/49 (6)		10/41 (24)		0/26 (0)
Relapse after untreated PR	2/54 (4)		1/49 (2)		3/41 (7)		0/26 (0)
Treated PR	0/54 (0)		1/49 (2)†		0/41 (0)		0/26 (0)
SD	2/54 (4)‡		0/49 (0)		0/41 (0)		0/26 (0)
Unknown	3/54 (6)†		0/49 (0)		0/41 (0)		0/26 (0)
Death after CR, CRu, untreated PR	1/54 (2)		8/49 (16)		1/41 (2)		8/26 (31)
EFS, PFS, OS rates with 95 CI
3-y EFS	38	25-52	43	29-57	57	42-73	65	47-84
3-y PFS	39	26-52	43	29-57	57	42-73	65	47-84
3-y OS	70	57-82	57	43-71	81	68-93	65	47-84

Treatment response rates patients in subgroup/total patients (percentage of total group), with the 95% CI in the adjacent column.

^*Seven patients randomized to allo-SCT are included.

^†Patients with no PTCL.

^‡Death after salvage treatment.